Current Edition

Upcoming Events


Haselmeier and Common Sensing Enter Connected Injectable Medicine Collaboration

Haselmeier, a Swiss-based developer and manufacturer of innovative self-injection devices, and Common Sensing, a Cambridge-based smart injector monitoring and support solutions company, today announced a partnership agreement to develop smart connected monitoring and support solutions for users of injectable medicines. Worldwide, over 16 billion injections of medicine are administered every year. Smart connected monitoring solutions for users of injectables is aimed helping them to properly administer those medicines to improve efficacy and quality of therapies.
Haselmeier’s subcutaneous drug delivery injection systems for self-administration will be combined with Common Sensing’s Gocap injector monitoring technology, creating a first-of-its-kind, next generation, smart disposable injector pen platform, to be available in 2019. This platform will be sold by Haselmeier and is expected to drive significant interest from new and existing Haselmeier injector customers. The combined injector pen-Gocap platform will record the time and amount of every injector dose, along with other information like storage temperature.
“Haselmeier is excited about the collaboration with Common Sensing. Both companies have recognized how complementary their technologies were and how much this partnership will provide value for both Companies and patients. The joint relationship we have built will enable Haselmeier and Common Sensing to rapidly bring a unique connected pen solution on the market,” said Paul Jansen, Haselmeier Senior Advisor and Board Member.
Gocap information may be made available for users, caretakers, clinicians, healthcare systems, researchers, and pharmaceutical companies. This information is a critical element of any connected health solution for people using injectable medicine. Gocap dose monitoring has been clinically validated for use with insulin pens in studies at the world-renowned Joslin Diabetes Center, in Boston, Massachusetts, and The University of Massachusetts Memorial Medical Center.
“This partnership is a fantastic, market shaping opportunity to merge the leading edge, Haselmeier D-Flex injector with our Gocap connected health technology in a scalable, commercial platform,” said Kevin Schmid, Common Sensing Chief Operating Officer.
Haselmeier has a history of developing innovative mechanical drug delivery solutions, including Haselmeier’s most recent and innovative D-Flex injector, which may be used with both fixed-dose or selectable dose regimen. The addition of a custom-designed Gocap injector monitor to the Haselmeier product portfolio will allow pharmaceutical customers to quickly launch connected injectable medicines into the market with existing and new Haselmeier pens.
“There is a high need to provide patients the means to better monitor the efficacy of their therapy and the injection experience is a crucial moment in a patient’s therapy. The collaboration of Haselmeier with Common Sensing is a smart and fast way to achieve our objective in improving patients’ lives,” said Frédéric Gabriel, Haselmeier Chief Strategy Officer.